Anti-peripheral lymph node addressin antibodies and uses thereof

A method of reducing tumor growth or metastasis of a peripheral lymph node addressin (PNAd)-expressing malignancy in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an anti-PNAd antibody, or PNAd-binding fragment thereof, wherein the anti-PNAd antibody or the PNAd-binding fragment thereof comprises:

• (a) a heavy chain variable region (VH), wherein the VH comprises a VH complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:
• 3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5;
• and
• (b) a light chain variable region (VL), wherein the VL comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:10;
• wherein the anti-PNAd antibody, or PNAd-binding fragment thereof, is conjugated to a therapeutic agent, wherein the therapeutic agent is a checkpoint inhibitor or a chemotherapeutic agent.